Akèy › Kansè Vezik ki pa envazif miskilè › New York › New York City
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan New York City, NY
10 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Ap rekriteFaz 2
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medical Center, New York
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Ap rekriteFaz 3
- Veterans Affairs New York Harbor Healthcare System-Manhattan Campus, New York
- Memorial Sloan Kettering Cancer Center, New York
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Ap rekriteFaz 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111), New York
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers, New York
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street, New York
- Icahn School of Medicine at Mount Sinai, New York
- ak 3 plis
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- Laura & Isaac Perlmutter Cancer Center - NYU Langone Health, New York
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- New York University (NYU), New York
- Weill Cornell Medicine, New York
- Icahn School of Medicine at Mount Sinai, New York
- ak 2 plis
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Ap rekriteFaz 3
- Columbia University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- NYU Langone's Perlmutter Cancer Center, New York
Etid Kansè Vezik ki pa envazif miskilè nan lòt vil
- Columbus, OH10 etid
- Dallas, TX10 etid
- Myrtle Beach, SC9 etid
- Edison, NJ9 etid
- Baltimore, MD8 etid
- Syracuse, NY8 etid
- Nashville, TN8 etid
- Houston, TX7 etid
- Indianapolis, IN7 etid
- Philadelphia, PA7 etid
- Birmingham, AL7 etid
- Atlanta, GA7 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.